Oral anticoagulant therapy has been shown to be effective for scveral indications. The optimal intcnsity of anticoagulation for each indication, howcver, is largely unknown. To determinc this optimal intensity, randomiscd clinical trials are conducted in which two target levcls of anticoagulation are compared. This approach is incfficicnt, since the choice of the target levels will bc arbitrary. Moreover, the achieved intcnsity is not taken into account.
Introduction
Several randomiscd clinical trials have been conducted, or are in progress, in which two intensities of oral anticoagulant therapy are compared prospcctively. This unfolding array of trial activity prescnts two problems to the field. First, it is unclcar how the target levels of anticoagulation which are contrasted in these trials are predcfined. Up to now, the choice of target levcls is largely arbitrary and thcreforc a sheer infinite scries of "trial and error" will inevitably follow. Second, the actually achieved intensity of anticoagulation is not taken into account. At best, the achieved intensity will fluctuatc around the target levcl in a way that is dependcnt on particular patient characteristics and local Organisation of anticoagulation monitoring. These randomiscd trials thcrefore offer only littlc Information about the optimal intensity of anticoagulation, for the pharmacologic effect and the effects of extrancous lactors influcncing anticoagulation are incxtricably intertwined.
Concspondcncc lo. Di. F. R. Roscndaal, Depaitmcnt ot Clinical Epidemiology, Bldg l, CO-P, Umvcisity Hospital Leiden, P.O Box 9600, NL-2300 RC Leiden, The Ncthcilands
The efficacy of oial anticoagulant treatment has been uncquivocally dcmonstrated for scveral indications. These include short term prophylaxis for venous thrombosis in high-risk situations, and short term treatment after an episode of deep venous thrombosis or pulmonary embolism. Long term treatment has bccn shown to bc bencficial in patients with mechanical heart valvcs, in patients with atrial fibrillation, and in patients suffering from coronary artery discasc (1) . For all these indications anticoagulant treatment has proved to be effective compared to placebo. The ncxt question is which intensity of anticoagulation offers the best benefit-risk-ratio, i.e., the optimal balance between thrombosis prevention and the occurrence of bleeding complications. This issue has gained rclevance since the development and Implementation of the ISI/INR System, which renders it possible to cxprcss the anticoagulation level, äs measured routinely and locally with one of the many available thromboplastins, in one standardised measure (2) .
Some of the trials in which two levcls of anticoagulation were compared, for instance in patients with bioprostheses of the heart valves (3) and in patients with mechanical heart valves (4), have shown target levels lower (i.e. less anticoagulation) than those usually recommended to be äs effective and äs safe äs the higher target levels. All these trials are obviously of the intention-totreat type, since it is impossible to maintain a completely stablc anticoagulant effect at the target level in all patients all of the time. Extraneous factors äs patient's compliance, physician's experience and variations in cumarin sensitivity in the individual paticnt will causc differences between the achieved intensity and the target level. Therefore, little insight is obtained about the risk of untoward effects at different intensities of anticoagulation.
This can be illustrated by the study of Saour et al. (4) , who compared target levels of INR 2.65 and INR 9.0 in patients with mechanical heart valves. In this study 33 thromboembolic events and 13 major bleedings were observed. The thromboembolic events were equally divided over both treatment groups, whereas most bleedings occurrcd in the group with the high target level. However, two-thirds of all thromboembolic events occurred at anticoagulation intensities (at the time of the event) below INR 2.65 and all occurrcd at intensities below INR 9.0. Similarly, in ninc of the 13 patients with major bleeding, the anticoagulation intensity exceeded INR 14 at the time of the event. So, most complications occurred in patients in whom the achieved intensity of anticoagulation at the time of the evenl was far from the intended intensity. In addition, one may question the generalisability from the results of a study of this design to other centers, since patient compliance and quality of anticoagulation monitoring may be quite different.
We propose a method to determine the optimal achieved intensity of anticoagulation. In our view, this method should not replacc, but precede trials in which target levels are compared, since knowledge of this optimal achieved intensity offers a rational starting point for setting the target levels in subsequent trials. In addition, our method will yield insight into the variability dt different taiget levels in a care System which is dcdicated but still belongs to medical routine
Method
Tho pioposcd mcthod mvolvcs tho calculation of mcidcncc latcs öl both typcs oi untowaid cvcnts (thiombocmbolism and blccding) loi ditfcicnt achicvccl mtcnsitics of anticoagulation To pcifoim thcsc calcu lations, a study timc fiamc has to bc dcdncd ovci which a cohoit oi paücnts is obscivcd The rcquircd inloimation includc Ihc datcs ot all piothiombin timc asscssmcnts and thc icsults ot Ihcsc mcasuicmcnts duiing thc obsoivation timc, äs well äs thc datcs of all cvcnt occuiicnccs and thc piothiombin timcs at thc timc öl thc cvcnts Covanatcs, cithci gencial such äs agc and gendci 01 spccific such äs hypeitcnsion, atnal tibnllation 01 co medication may be icgistcicd and mcoipoialcd by stiatiticd analysis 01 multivaiiatc modclmg by Poisson icgicssion Bctoic dcscubing thc spccilic apphcation ot thc calculation ot mcidcncc latcs in anticoagulatcd paticnts, wc will discuss thc conccpts ot mcidcncc latcs and thc catcgonsation ot mcidcncc latcs
Incidence Rates
Mathcmatically, thc mcidcncc latc (mcidcncc dcnsity 01 hazaid lalc) is Ihc instantancous piobability ot an cvcnt occuncncc Thc avciagc mcidcncc latc is thc numbci of cvcnts dividcd by thc obscivation timc, ususally cxpicsscd m paticnt-ycais It appioximatcs thc instantancous mcidcncc latc by thc assumption that ovci short obscivation intcivals Ihc piobability oi discasc is piopoitional to thc obscivation timc, i c , 10 paticnts tollowcd toi 2 ycais will yicld thc samc mcidcncc äs 20 paticnls tollowcd loi l ycai Undci this assumption, thc mcidcncc täte is casily calculatcd by dcteimmmg thc numbci of evcnts and dividing this tiguic by thc s u m of thc obscivatiön timcs of all paticnts m thc cohoit (5) Foi cach individual paticnt, thc obscivation timc is countcd tiom his cntiy in thc study until cithci thc cnd ot Ihc study timc fiamc 01 thc timc of an cvcnt, whichcvci occuis tust Thc piobability of an cvcnt ovci a ccitam timc mtcival (cumulative mcidcncc) can bc dcnvcd tiom thc mcidcncc latc by a simple cxponcntial tianstoimation (5, 6)
Calegoii^ation of the Obieivation Time
In thc simplest foim, thc mcidcncc is calculated foi onc, unstiatificd cohoit, by dividing the numbci oi cvcnts by thc sum ot thc obscivation timcs of all patients m thc cohoit A first cxtcnsion is stiatitication ovci fixcd covanatcs, such äs scx In this casc all mcn conlnbutc pcison timc only to Ihc male stialum and all womcn only to thc tcmalc stiatum, with Ihc icsult ot two scx-spccilic mcidcncc latcs Smcc, howcvci thc only constitucnts öl thc mcidcncc latcs aic thc stiatum-spccitic numbci of cvcnts, and thc stiatum-spccitic total obsciva tion limc, it is not icquncd that paticnts only contnbutc paticnt-timc to onc stiatum Whcn stiatification is pcitoimcd on untixcd covanatcs, such äs calcndai-pciiod oi agc äs is usually donc to allow standaidiscd companson ot two mcidcncc latcs, onc paticnt may contubutc pcisontmic to scvcial stiata
Application to the Level of Anticoagulation
Fully analogous lo thc catcgonsation ot thc pcison timc in cclls clctcimmcd by agc scx and calcndai pcnods, thc obscivation timc may bc biokcn down in cclls of thc achicvcd Icvcl of anticoagulation Thc mcidcncc latc ot cvcnts at cach Icvcl öl anticoagulation is agam calculatcd äs thc ratio ot thc numbci ot cvcnts occuinng at a paiticulai mtcnsily, ovci thc summcd pcison timc at that mtcnsity
Evenls at Each Level (Incidence Numeiatoi)
Dcpcndcnt on thc cvcnts thc study is aimed al, a System has to bc sct up m which all cvents aic icgistcicd It sccms most piactical lo limit thc study to scverc complications i c those that icqune hospitahsation 01 Icad to dcath Ideally, onc has to know thc mtcnsity ot anticoagulation at thc timc of thc cvcnt In casc ot hospitahsation, a piothiombin timc will usually bc pcrfoimcd Whcn this has not bccn donc thc only appioxima tion ot the anlicoagulation Icvcl a thc timc of thc cvcnt is that of thc last mcasuicmcnt bctoic thc cvcnt occuiied
Calculation of ihe Obieivation Time foi Diffeient Levels (Incidence Denominatoi)
Foi cach paticnt, piothiombin timcs have bcen mcasuicd at fixcd 01 vanablc mtcivals, thc Icngth of which timc mtcivals is known Wc assumc that thc INR valuc bclwccn two mcasuicments will vaiy Imcaily tiom thc valuc ot thc tust, lo thc valuc of thc sccond mcasuicmcnt With this assumption, two appioachcs may bc cmploycd to allocatc the peison-Ume bctwccn two mcasuicmcnls lo paiticulai INR valucs Thc most simple appioximation is to clividc thc timc betwccn two mcasuicmcnt in halvcs, and allocatc thc tust halt to thc INR valuc oi thc fnst, and thc sccond halt lo thc INR valuc of thc second measuicmcnt So, it a 2-weck mtcival is boundcd by a piothiombin Urne of 3 (Fig 2) A sccond, moic accuratc appioach is lo dividc Ihc Urne bctwccn two mcasuicmcnts in days, and lo usc small stcps ot 0 l INR ovci thc lange ot thc timc mlcival In llus appioach, Ihc INR is licalcd äs giadually mcicasmg 01 dccicasmg ovci Ihc mtcival In thc cxamplc abovc, 2 days aic allocatcd lo an INR ot 3 6, 2 days to an INR ot 3 7, and so on Subscqucnlly, Ihc pcison limc of thcsc small stcps is collapscd mlo laigei cclls of 0 5 oi 10 INR and Ihcn summcd ovci all palicnls Wc havc dcvclopcd Software lo pciloim Ihcsc calculations on a pcisonal compulci 
Analysis
Smcc the numbci ot events at cach intcnsity and thc summcd pcisontime at cach intcnsity aic now known, mcidcncc lales at cach intcnsity can bc calculatcd Thc cclls may bc luithci sliatified by scx, agc and othci covaiiatcs, and by application oi a multivaiialc Poisson icgicssion modcl incidcnce lato latios at the ditteicnt mtcnsitics may bc calculated, to contiol loi contounding by this covaiiatcs and to cxaminc thc nsk ot comphcations associatcd with thcsc covanates Standaid cnois toi thc mcidcncc latcs and thc mcidcncc lato latios can bc dcnved in thc standaid tashion bascd on thc assumption ot a Poisson distnbution ot thc numbci of cvents These multivauatc analyscs can bc pcitoimcd by sevcial ot thc commcicially availablc soltwaic packagcs
In thc sccond study, wc usc this mcthod to mvestigate nsk factois toi blccdmg m unsclcctcd paticnts who icceive anticoagulant trcatment foi vanous mdication (8) To this cftect, wc study mmoi and ma]Oi bleedmg comphcations duimg l ycai m thc ovci 6,800 patients tieated by the Leiden Thiombosis Scivicc annuall) In this mstancc, the mcthod scivcs two puiposcs Fnst wc exammc the nsk ot blccdmg toi ditteicnt mtcnsilics ot anticoagulation Second wc can by multivauatc analysis, usc thc mtensitics äs an ad|ustmcnt tactoi and mvcstigale thc contnbution ot othci tactoi s to the nsk ot blccdmg mdcpcndcnt ot thc aclucvcd intcnsity ot anticoagulation Yet anothci application ot this mcthod is äs a mcasuic foi the quality of anticoagulation monitonng which is now usually given äs thc pciccnt agc of piothiombm timcs within thc taigct zones By calculating thc peison-timc spent at cach intcnsity of anticoagulation wc can cxpicss thc quality öl monitonng äs thc pciccntagc of thc total pcison timc that lies within thc taigct zoncs
Application of the Melhod
This mcthod can bc apphcd ictiospectivcly, on data loutincly icgisteicd by a thiombosis scivtcc, äs well äs piospcctivcly äs a secondaiy analysis within a landomizcd lnal Thc method is piescntly cmploycd in two studies In thc tust onc, thc Leiden Aititicial Valves and Anlicoagula tion study (LAVA), wc scck thc optimal intcnsity ot achieved anücoagu lation m paticnts with mechanical hcail valvcs äs thc Icvcl at which thc mcidcncc ot stiokc, combinmg intaiclion and bleedmg, is lowcst Smcc the nsk ot thiombosis on a mechanical valvc and subscqucnl ccicbial cmbohsm is high in thc abscncc öl anticoagulation ticatmcnt (appioximalcly 1-5% pei yeai), paticnts with mechanical hcait valvcs aic mtcnscly anticoagulatcd (taigct lange m Thc Nctheilands 3 6-4 8 INR) This imphcs that thc nsk öl majoi blcedmgs, ot which ccicbial hemoi ihagc is the most scvcic, is iclativcly high, and thc balancc bctwccn thiombosis piophylaxis and iisk of blccdmg piccious It is icasonablc to assumc lhat thc nsk of ccicbial cmbohsm and mtaiction mcieascs with lowci mtensitics ot anticoagulation, whcicas thc nsk ot ccicbial blccdmg mcieascs with highci mtcnsilics (Fig 3) So, wc cxpcct that thc mcidcncc ot stiokc will havc a U-shapcd distnbution ovci the lange oi aclucvcd mtensitics Piclimmaty icsults mdicatc that this U-shapcd distnbution docs cxist (7) Foi this analysis, it is not cvcn ncccssaiy to distinguish bctwccn ccicbial mfaictions and ccicbial blccdmg and it avoids thc ditticult task ot classitymg a hcmonhagic inlaiction äs cithei mtaiction 01 bleedmg Smcc wc aic mtcicsted in the level ot anticoagulation that has thc lowcst i isk ot stiokc, whatevci its oiigm, it is ot moie iclcvancc to usc a chnical classitication System bascd on thc scventy ot thc scquclac ot the stiokc
Inoidence rates
Intensity of OAC   Fig 3 Thcoictical iclation öl the mcidcncc öl thiombocmbohsm and blccdmg with thc achieved intcnsity öl anticoagulation Thc iisk ot thiombocmbohsm dccicascs exponentially with incicascd mtensitics of anticoagulation, whcicas thc nsk of bleedmg mcieascs exponentially Thc lowcst mcidcncc öl untowaid cttccts ι c thc mmimum of thc supciim poscd giaphs, dcnoles thc optimal intcnsity of anticoagulation
Discussion
We have proposed a method that allows assessment of the optimal achievcd intcnsity of anticoagulation by the calculation of INR-specific mcidence ratcs of untoward evcnts The rcsults of analysis by this method can bc used to sct the target rangcs for chnical tuals on oral anticoagulation tor vanous indications In addition, the method can bc cmployed to detcrmme nsk factors for comphcations, thiombosis or blccdmg, adjusted for the achieved level of anticoagulation A prcrequisite for the usc of this method is careful observation of all complication If, howevcr, this is donc routincly, äs in the Dutch Thiombosis Seivices, and if dates and lesults of prothrombm time mcasurements are stored in compuleis over longer penods of time, this method can bc apphcd rctiospcctively to large numbers of patients, and precise estimates may bc expected
One of the assumptions of the allocation of person-time to diffeient mtensitics of anticoagulation is a linear mcrease or decrease of the anlicoagulation effect between subsequcnt mcasurements It may well be, however, that the change is greatest shortly aftcr a measuiement has been performed and a dose adjustment has been made, in particular when a prothrombm mcasurcment shows excessive under-or overanticoagulation, in which casc a boostei-dose or Vitamin K may be prescnbed We feel that these effects will probably cven out m the broad ränge aiound the target values, encompassmg the majonty of mcasuiements This is especially so since the INR categones are broadly chosen, with mtcivals of 0 5 or l 0 INR For extreme values, there may be a bias, with an overcstimatc of the pcrson-timc at vcry Iow, and at very high INR values This imphcs that the mcidence ratcs at thesc extremes will be undeiestimated Since the optimal Icvcl will not be located at these extreme values, we considei this of minor importance It must bc notcd that this leasoning becomes Icss vahd whcn anticoagulation contiol is of veiy pooi quahty, i e when all stabihty in anticoagulation is lacking Assessment of the optimal achieved level öl anticoagulation should precede studies comparing diffeient target levels Since it is not possible to maintam an optimal level m all patients constantly, subsequcnt chnical tnals lemain nccessaiy, to evaluate target levels set at or around the optimal achieved intensity on an intention-to-treat basis
